Reliability of CancerGuard (Multicancer Early Detection Blood Test) for Cancer Screening in Asymptomatic Individuals
CancerGuard is a multicancer early detection (MCED) blood test marketed for use in people without cancer symptoms. Current evidence is insufficient to support CancerGuard as a reliable cancer screening tool for asymptomatic individuals. [1], [2]
Regulatory Status and Guideline Position
CancerGuard is not cleared or approved by the FDA as an MCED screening test. [1]
Diagnostic Performance in Screening-Like Settings
MCED test performance in screening-like studies shows limited sensitivity for detecting cancer and substantial downstream false-positive evaluations. [2]
Benefits That Are Not Yet Proven
A reduction in cancer mortality from MCED testing has not been established for asymptomatic screening populations. [1]
Harms From Follow-Up Testing After Positive Results
False-positive MCED results can trigger additional diagnostic workup, including PET-CT exposure in study settings, with clinically meaningful downstream testing burden. [2]
Practical Interpretation of “Positive” Results
A positive MCED test result does not establish the presence of cancer and requires confirmatory diagnostic evaluation. [3]
Screening Alternatives With Established Benefit
Established screening programs for specific cancer sites (for example, breast, colorectal, cervical, prostate, and lung cancer) are recommended instead of MCED testing. [1], [4]
Evidence Standard Needed Before Reliable Widespread Screening
Reliable screening requires demonstrated clinical utility (improved health outcomes such as mortality reduction) in asymptomatic populations. [1], [2]